NEWS HIGHLIGHTSMedia Articles Related to Uroxatral (Alfuzosin)
Effects Of Once-Daily Tadalafil On Erectile Function In Men With Erectile Dysfunction And Signs And Symptoms Of Benign Prostatic Hyperplasia
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2009.07.12]
UroToday.com - Men with benign prostatic hyperplasia (BPH) often suffer from lower urinary tract symptoms (LUTS; BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. BPH-LUTS and erectile dysfunction (ED), both highly prevalent conditions in aging men, are frequently associated in the same men, may have common pathophysiological mechanisms, and contribute negatively to quality of life.
Benign Prostatic Hyperplasia
Source: MedicineNet doxazosin mesylate Specialty [2008.06.23]
Title: Benign Prostatic Hyperplasia
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 6/23/2008
Published Studies Related to Uroxatral (Alfuzosin)
Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. [2009.04]
OBJECTIVES: To study the efficacy of alfuzosin compared with tamsulosin in the management of lower ureteral stones... CONCLUSIONS: Medical treatment of lower ureteral calculi with tamsulosin and alfuzosin resulted in a significantly increased stone expulsion rate, decreased expulsion time, and a reduced need for analgesic therapy.
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. [2009.02]
INTRODUCTION: Alpha1-blockers (AB) are the first-line monotherapy for lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors are the first-line treatment for erectile dysfunction (ED). Numerous studies have supposed a significant association between ED and LUTS, but a causal relationship cannot be established. AIM: The aim was to evaluate the efficacy of a combined therapy with an AB (alfuzosin) and PDE5 inhibitors (tadalafil) in patients with LUTS and ED... CONCLUSIONS: Combined therapy improved ED and LUTS as demonstrated by the significant improvement in uroflowmetry measures and in IPSS and IIEF-EF scores. A significant improvement was also observed in quality of life assessments. The beneficial effects of tadalafil on LUTS similar to the benefits of alfuzosin on ED, although present, were smaller.
Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. [2009.01]
PURPOSE: We assessed the impact of alfuzosin on ureteral stent discomfort... CONCLUSIONS: Alfuzosin improves the patient discomfort associated with ureteral stents by decreasing urinary symptoms and kidney pain but it does not affect the amount of narcotics that patients use while the stent is in place.
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. [2008.12.18]
BACKGROUND: In men with chronic prostatitis-chronic pelvic pain syndrome, treatment with alpha-adrenergic receptor blockers early in the course of the disorder has been reported to be effective in some, but not all, relatively small randomized trials... CONCLUSIONS: Our findings do not support the use of alfuzosin to reduce the symptoms of chronic prostatitis-chronic pelvic pain syndrome in men who have not received prior treatment with an alpha-blocker. (ClinicalTrials.gov number, NCT00103402.) 2008 Massachusetts Medical Society
Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study. [2008.06]
PURPOSE: We evaluated the efficacy of alfuzosin as medical expulsive therapy for distal ureteral stone passage... CONCLUSIONS: Alfuzosin improves the patient discomfort associated with stone passage and decreases the time to distal ureteral stone passage but it does not increase the rate of spontaneous stone passage.
Clinical Trials Related to Uroxatral (Alfuzosin)
The Long Term Effects of Alfuzosin(Xatral XL) in LUTS/BPH Patients: Evaluation of Voiding and Storage Function [Active, not recruiting]
Benign prostatic hyperplasia (BPH) is a common condition among older men. The efficacy of
α1-blockers for treating BPH has been well documented and they are recommended for the
treatment of BPH by clinical guidelines.
It is not well known if a stratification based on the grade of BOO and bladder contractility
has any predictive value for patients who are treated with an α1-selective blocking agent. In
our study, we investigated possible differences in treatment outcome between patients with
and without BOO, and with or without proper contractility who are treated with alfuzosin. So
we will compare the quantified improvements 12 months after alfuzosin medication in LUTS/BPH
patients by the grade of BOO and/or bladder contractility.
Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy [Completed]
To collect under daily practice conditions, clinical data on the changes of sexual function
when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with
lower urinary tract symptoms(LUTS) suggestive of prostatic hypertrophy
Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study [Completed]
To assess, under daily practice conditions, the safety profile and the efficacy of a new
formulation of alfuzosin administered once daily (Xatral XL) in patients with lower urinary
tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Once Daily Given Alfuzosin in the Treatment of BPH [Completed]
Collection of the data on the safety and efficacy of the once daily administration of the
alfuzosin preparation /Alfetim Uno® l0 mg/ at patients with lower urinary tract
symptoms/complaints rendering possible the presence of benign prostatic hyperplasia, in the
course of everyday practice
Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome [Completed]
The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the
alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic
prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg
capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH).
The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH
has been documented in a number of placebo-controlled studies. A number of small studies
have also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar
alpha-blockade mechanism. This study will enable further testing of this hypothesis
|
